On March 19, Bristol-Myers Squibb (BMS) announced that its dual immunotherapy combination Opdualag had received accelerated marketing approval from the FDA. Opdualag therapy is a fixed-dose combination of Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma, making LAG-3 the third immune checkpoint in the clinic after PD-1 and CTLA-4.
Lymphocyte-activation gene 3 (LAG-3), also known as CD233, is a type I transmembrane protein expressed mainly in activated T cells, NK cells, B cells, and plasma cell-like DCs. Oncology and autoimmune diseases (rheumatoid arthritis, multiple sclerosis) are currently among the clinical pipeline indications for LAG-3 which acts as an immunomodulator in a variety of tumors, including leukemia, non-small cell lung cancer, colon cancer, pancreatic cancer, and head and neck cell cancer. As an important member of tumor immunotherapy, LAG-3 antibodies have large future market potential.
The membrane protein encoded by the LAG3 gene contains four immunoglobulin superfamily structural domains that are very similar to CD4 in terms of structure and chromosomal localization, but it binds with higher affinity to MHCII (major histocompatibility complex class II molecule) and negatively regulates T cell function.
The main mechanism of action of LAG-3
* Bind to Galectin-3 and LSECtin, which affect T cell function.
* Elevated plasma levels of FGL1 in tumor patients are associated with poor prognosis and resistance to PD-1 inhibitors. Block FGL1-LAG-3 interaction to enhance the anti-tumor effect.
The combined therapy of CTLA-4 and PD-1/PD-L1 is well established. The LAG-3/PD-1 combination must not only outperform PD-1 alone, but inevitably also has to contest with CTLA-4/PD-1 combinations.
Results from the phase II/III study of RELATIVITY-047 (CA224-047) showed that in 714 patients with previously untreated metastatic or unresectable melanoma treated with Relatlimab in combination with Opdivo, compared to Opdivo monotherapy, the median progression-free survival (mPFS) in the former was 10.1 months compared to 4.6 months in the latter. The 12-month PFS rate was 47.7% in the Relatlimab-Opdivo group compared with 36.0% in the Opdivo group.
Relatlimab outperformed CTLA-4 monoclonal antibody Ipilimumab in terms of safety. 59% of patients treated with Ipilimumab + Opdivo experienced serious or life-threatening side effects, compared to a grade 3 or 4 Relatlimab treatment-related adverse event rate of only 18.9%.
There are currently 50+ drugs in the pipeline that target LAG-3, and the development of a LAG-3 immune checkpoint inhibitor is set to take off again with the approval of Relatlimab.
Roots Analysis has done a detailed study on Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link Key Market Insights More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indicationsThe pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routesIn the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwideIn the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effortSeveral organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targetsThe growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholdersThe future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regionsIn the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration For more information, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Table of Contents PREFACE 1.1.
Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers 4.4.1.
Word Cloud: Key Focus Areas 7.3.9.
Next Generation Immune Checkpoint Therapeutics Portfolio 8.2.4.
Analysis by Funding Institute Center 9.3.5.
Immune Checkpoint Inhibitors Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.Get FREE Sample Report Before Buying @ https://www.upmarketresearch.com/home/requested_sample/8160UpMarketResearch offers a latest published report on “Global Immune Checkpoint Inhibitors Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage to clients through a detailed report.
The report contains 109 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.Immune Checkpoint Inhibitors Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
Secondary research techniques are implemented for better understanding and clarity for data analysis.The report for Immune Checkpoint Inhibitors market analysis & forecast 2018-2023 is segmented into Product Segment, Application Segment & Major players.Region-wise Analysis Global Immune Checkpoint Inhibitors Market covers:North AmericaEuropeChinaJapanIndiaSoutheast AsiaOther regions (Central & South America, Middle East & Africa)The Major players reported in the market include:Bristol Myer SquibbAstraZenecaMerck & Co.Roche / GenentechIncyte CorporationNewLink GeneticsArGEN-XSeattle GeneticsPfizerMacroGenicsCelldex TherapeuticsCureTechImmutepInnate PharmaSorrento TherapeuticsGlaxoSmithKlineGITR, IncFor More Information, Please Visit https://www.upmarketresearch.com/home/enquiry_before_buying/8160Global Immune Checkpoint Inhibitors Market: Product Segment Analysis:PD-1/PD-L1CTLA-4Global Immune Checkpoint Inhibitors Market: Application Segment Analysis:Lung CancerColorectal CancerBreast CancerProstate CancerMelanomaBlood CancerOtherThe Report covers in-depth analysis as follows:Chapter 1 Study CoverageChapter 2 Executive SummaryChapter 3 Breakdown Data by ManufacturersChapter 4 Breakdown Data by TypeChapter 5 Breakdown Data by ApplicationChapter 6 North AmericaChapter 7 EuropeChapter 8 Asia PacificChapter 9 Central & South AmericaChapter 10 Middle East and AfricaChapter 11 Company ProfileChapter 12 Market Opportunities, Challenges, Risks and Influences Factors AnalysisBuy Immune Checkpoint Inhibitors Market analysis & forecast 2018-2023 Report along with complete TOC @https://www.upmarketresearch.com/buy/immune-checkpoint-inhibitors-market“Immune Checkpoint Inhibitors Market Analysis and Forecast 2018-2023” report helps the clients to take business decisions and to understand strategies of major players in the industry.
